US6217911B1
(en)
|
1995-05-22 |
2001-04-17 |
The United States Of America As Represented By The Secretary Of The Army |
sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
|
USRE40786E1
(en)
|
1984-03-16 |
2009-06-23 |
The United States Of America As Represented By The Secretary Of The Army |
Vaccines against intracellular pathogens using antigens encapsulated within biodegradable-biocompatible microspheres
|
US6309669B1
(en)
|
1984-03-16 |
2001-10-30 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
|
US6410056B1
(en)
|
1984-03-16 |
2002-06-25 |
The United States Of America As Represented By The Secretary Of The Army |
Chemotherapeutic treatment of bacterial infections with an antibiotic encapsulated within a biodegradable polymeric matrix
|
US5693343A
(en)
|
1984-03-16 |
1997-12-02 |
The United States Of America As Represented By The Secretary Of The Army |
Microparticle carriers of maximal uptake capacity by both M cells and non-M cells
|
NZ217821A
(en)
*
|
1985-10-10 |
1989-07-27 |
Biotech Australia Pty Ltd |
Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
|
US5811128A
(en)
*
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
US5807832A
(en)
*
|
1987-06-09 |
1998-09-15 |
Biotech Australia Pty Limited |
Oral delivery of biologically active substances bound to vitamin B12
|
US5116612A
(en)
*
|
1987-06-23 |
1992-05-26 |
Allergy Immuno Technologies, Inc. |
Immunotherapy agents for treatment of IgE mediated allergies
|
AU639903B2
(en)
*
|
1989-01-20 |
1993-08-12 |
University Of Melbourne, The |
Fibrinolysis
|
US5236705A
(en)
*
|
1989-01-20 |
1993-08-17 |
The University Of Melbourne |
Fibrinolysis
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
WO1990013361A1
(en)
*
|
1989-05-04 |
1990-11-15 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
US6126945A
(en)
*
|
1989-10-03 |
2000-10-03 |
Pharmacia Ab |
Tumor killing effects of enterotoxins, superantigens, and related compounds
|
DK546289D0
(da)
*
|
1989-11-02 |
1989-11-02 |
Danochemo As |
Carotenoidpulvere
|
CA2071867A1
(en)
*
|
1989-11-06 |
1991-05-07 |
Edith Mathiowitz |
Method for producing protein microspheres
|
US5882649A
(en)
*
|
1990-04-24 |
1999-03-16 |
Flustat Pty. Ltd. |
Oral vaccine comprising antigen surface-associated with red blood cells
|
BR9106374A
(pt)
*
|
1990-04-24 |
1993-03-30 |
Univ Newcastle Res Ass |
Vacina oral e processo de extrair uma imunoresponsta em um mamifero
|
US5780012A
(en)
*
|
1990-06-21 |
1998-07-14 |
Huland; Edith |
Method for reducing lung afflictions by inhalation of cytokine solutions
|
EP0462305B1
(de)
*
|
1990-06-21 |
1994-11-02 |
Huland, Edith, Dr. Dr. |
Verwendung zytokinhaltiger Aerosole und zytokinhaltige Aerosole selbst
|
NZ242220A
(en)
*
|
1991-04-02 |
1994-04-27 |
Biotech Australia Pty Ltd |
Complex for oral delivery of a substance to the circulatory or lymphatic drainage system comprising microparticle coupled to at least one carrier, the substance being encapsulated by the microparticle
|
AU8303691A
(en)
|
1991-04-24 |
1992-12-21 |
United States Of America, As Represented By The Secretary Of The Army, The |
Oral-intestinal vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
|
US5283066A
(en)
*
|
1992-02-19 |
1994-02-01 |
Development Center For Biotechnology |
Method of stimulating an immune response by using a hapten
|
US5352461A
(en)
*
|
1992-03-11 |
1994-10-04 |
Pharmaceutical Discovery Corporation |
Self assembling diketopiperazine drug delivery system
|
US6197346B1
(en)
|
1992-04-24 |
2001-03-06 |
Brown Universtiy Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
US6235313B1
(en)
|
1992-04-24 |
2001-05-22 |
Brown University Research Foundation |
Bioadhesive microspheres and their use as drug delivery and imaging systems
|
US5922340A
(en)
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
US5700485A
(en)
*
|
1992-09-10 |
1997-12-23 |
Children's Medical Center Corporation |
Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
|
JP3007687B2
(ja)
*
|
1992-09-10 |
2000-02-07 |
チルドレンズ メディカル センター コーポレイション |
局所麻酔剤の持続性送達のための生分解性ポリマーマトリックス
|
AU4932493A
(en)
*
|
1992-09-25 |
1994-04-26 |
Dynagen, Inc. |
An immunobooster for delayed release of immunogen
|
EP0646000A4
(en)
*
|
1992-11-16 |
1997-05-02 |
Univ Mercer |
COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
|
ES2095001T5
(es)
*
|
1992-12-22 |
2001-03-16 |
Univ Cincinnati |
Una composicion terapeutica administrable oralmente y su metodo de obtencion.
|
US6090925A
(en)
|
1993-03-09 |
2000-07-18 |
Epic Therapeutics, Inc. |
Macromolecular microparticles and methods of production and use
|
US6939546B2
(en)
|
1993-05-21 |
2005-09-06 |
The United States Of America As Represented By The Secretary Of The Army |
Model for testing immunogenicity of peptides
|
US5603960A
(en)
*
|
1993-05-25 |
1997-02-18 |
O'hagan; Derek T. |
Preparation of microparticles and method of immunization
|
US5562909A
(en)
*
|
1993-07-12 |
1996-10-08 |
Massachusetts Institute Of Technology |
Phosphazene polyelectrolytes as immunoadjuvants
|
WO1995003035A1
(en)
*
|
1993-07-23 |
1995-02-02 |
Massachusetts Institute Of Technology |
Polymerized liposomes with enhanced stability for oral delivery
|
US6004534A
(en)
*
|
1993-07-23 |
1999-12-21 |
Massachusetts Institute Of Technology |
Targeted polymerized liposomes for improved drug delivery
|
ATE175110T1
(de)
*
|
1993-10-22 |
1999-01-15 |
Genentech Inc |
Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
|
DE69431404T2
(de)
*
|
1993-10-22 |
2003-04-30 |
Genentech Inc., San Francisco |
Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
|
JPH09504523A
(ja)
*
|
1993-10-22 |
1997-05-06 |
ジェネンテク,インコーポレイテッド |
アジュバントのマイクロカプセル化方法および組成物
|
US6913767B1
(en)
|
1993-10-25 |
2005-07-05 |
Genentech, Inc. |
Compositions for microencapsulation of antigens for use as vaccines
|
US5643605A
(en)
*
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
US6080429A
(en)
*
|
1993-10-25 |
2000-06-27 |
Genentech, Inc. |
Method for drying microspheres
|
JP3645906B2
(ja)
|
1993-11-19 |
2005-05-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
マイクロカプセル封入された3−ピペリジニル−置換1,2−ベンズイソオキサゾール類及び1,2−ベンズイソチアゾール類
|
US5902565A
(en)
*
|
1993-12-24 |
1999-05-11 |
Csl Limited |
Spray dried vaccine preparation comprising aluminium adsorbed immunogens
|
US6531156B1
(en)
|
1994-04-15 |
2003-03-11 |
Temple University |
Aqueous solven encapsulation method, apparatus and microcapsules
|
US5876735A
(en)
*
|
1994-04-22 |
1999-03-02 |
Corixa Corporation |
Methods for enhancement of protective immune responses
|
US6013268A
(en)
|
1994-04-22 |
2000-01-11 |
Corixa Corporation |
Methods for enhancement of protective immune responses
|
US6855331B2
(en)
|
1994-05-16 |
2005-02-15 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
US5571531A
(en)
*
|
1994-05-18 |
1996-11-05 |
Mcmaster University |
Microparticle delivery system with a functionalized silicone bonded to the matrix
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US5821226A
(en)
*
|
1994-12-01 |
1998-10-13 |
Oklahoma Medical Research Foundation |
BAL C-tail drug delivery molecules
|
US5681819A
(en)
*
|
1994-12-01 |
1997-10-28 |
Oklahoma Medical Research Foundation |
Method and compositions for reducing cholesterol absorption
|
US5696087A
(en)
*
|
1994-12-01 |
1997-12-09 |
Oklahoma Medical Research Foundation |
Method and compositions for reducing cholesterol absorption
|
US6902743B1
(en)
|
1995-05-22 |
2005-06-07 |
The United States Of America As Represented By The Secretary Of The Army |
Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
|
US7033608B1
(en)
|
1995-05-22 |
2006-04-25 |
The United States Of America As Represented By The Secretary Of The Army |
“Burst-free” sustained release poly-(lactide/glycolide) microspheres
|
CN1156961A
(zh)
|
1995-06-09 |
1997-08-13 |
欧罗赛铁克股份有限公司 |
产生长效局部麻醉的制剂和方法
|
US6143211A
(en)
|
1995-07-21 |
2000-11-07 |
Brown University Foundation |
Process for preparing microparticles through phase inversion phenomena
|
US6248720B1
(en)
|
1996-07-03 |
2001-06-19 |
Brown University Research Foundation |
Method for gene therapy using nucleic acid loaded polymeric microparticles
|
JPH11510142A
(ja)
*
|
1995-07-21 |
1999-09-07 |
ブラウン・ユニバーシティ・リサーチ・ファンデーション |
核酸負荷ポリマー微粒子を使用した遺伝子治療法
|
KR100433750B1
(ko)
|
1995-09-01 |
2004-09-01 |
코릭사 코포레이션 |
마이코박테리움튜베르큘로시스항원을포함하는폴리펩타이드및이를포함하는약제학적조성물
|
EP0862419B2
(en)
†
|
1995-11-09 |
2010-11-17 |
Microbiological Research Authority |
Microencapsulated dna for vaccination and gene therapy
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
US5985312A
(en)
*
|
1996-01-26 |
1999-11-16 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6368586B1
(en)
|
1996-01-26 |
2002-04-09 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers
|
US6342218B1
(en)
|
1997-02-14 |
2002-01-29 |
Oklahoma Medical Research Foundation |
Method for treatment of SLE
|
US6015576A
(en)
*
|
1997-08-29 |
2000-01-18 |
Bio-Sphere Technology, Inc. |
Method for inducing a systemic immune response to an antigen
|
US6117449A
(en)
*
|
1996-03-22 |
2000-09-12 |
Bio-Sphere Technology, Inc. |
Method for inducing a systemic immune response to a hepatitis antigen
|
US6207185B1
(en)
|
1996-03-22 |
2001-03-27 |
Bio-Sphere Technology |
Method for inducing a systemic immune response to an HIV antigen
|
US6652837B1
(en)
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
US20020052310A1
(en)
*
|
1997-09-15 |
2002-05-02 |
Massachusetts Institute Of Technology The Penn State Research Foundation |
Particles for inhalation having sustained release properties
|
US5985309A
(en)
*
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
US5874064A
(en)
*
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
AU733867B2
(en)
|
1996-06-24 |
2001-05-31 |
Euro-Celtique S.A. |
Methods for providing safe local anesthesia
|
US5955096A
(en)
*
|
1996-06-25 |
1999-09-21 |
Brown University Research Foundation |
Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
|
US6344202B1
(en)
*
|
1996-07-12 |
2002-02-05 |
University Of Manitoba |
DNA immunization against chlaymdia infection
|
US5980948A
(en)
*
|
1996-08-16 |
1999-11-09 |
Osteotech, Inc. |
Polyetherester copolymers as drug delivery matrices
|
US6046187A
(en)
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
US5783567A
(en)
*
|
1997-01-22 |
1998-07-21 |
Pangaea Pharmaceuticals, Inc. |
Microparticles for delivery of nucleic acid
|
WO1998031398A1
(en)
*
|
1997-01-22 |
1998-07-23 |
Zycos Inc. |
Microparticles for delivery of nucleic acid
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
BR9807332A
(pt)
|
1997-02-12 |
2000-10-31 |
Corixa Corp |
Antìgenos de leishmania para utilização na terapia e diagnóstico de leishmaniose
|
US6261562B1
(en)
|
1997-02-25 |
2001-07-17 |
Corixa Corporation |
Compounds for immunotherapy of prostate cancer and methods for their use
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
EP1003501B9
(en)
|
1997-04-02 |
2005-06-08 |
The Brigham And Women's Hospital, Inc. |
Use of an agent for lowering the risk of cardiovascular disease
|
ZA982968B
(en)
|
1997-04-09 |
1998-10-27 |
Corixa Corp |
Compositions and methods for the treatment and diagnosis of breast cancer
|
US6060082A
(en)
|
1997-04-18 |
2000-05-09 |
Massachusetts Institute Of Technology |
Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
|
WO1999001114A1
(en)
|
1997-07-02 |
1999-01-14 |
Euro-Celtique, S.A. |
Prolonged anesthesia in joints and body spaces
|
WO1999009956A1
(en)
*
|
1997-08-29 |
1999-03-04 |
Corixa Corporation |
Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
|
EP1579851A3
(en)
*
|
1997-08-29 |
2009-09-02 |
Corixa Corporation |
Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of use thereof
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6946117B1
(en)
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US6013258A
(en)
*
|
1997-10-09 |
2000-01-11 |
Zycos Inc. |
Immunogenic peptides from the HPV E7 protein
|
US6183746B1
(en)
*
|
1997-10-09 |
2001-02-06 |
Zycos Inc. |
Immunogenic peptides from the HPV E7 protein
|
US6197229B1
(en)
*
|
1997-12-12 |
2001-03-06 |
Massachusetts Institute Of Technology |
Method for high supercoiled DNA content microspheres
|
AU6253898A
(en)
*
|
1997-12-16 |
1999-07-05 |
Chiron Corporation |
Use of microparticles combined with submicron oil-in-water emulsions
|
US7393630B2
(en)
|
1997-12-16 |
2008-07-01 |
Novartis Vaccines And Diagnostics, Inc. |
Use of microparticles combined with submicron oil-in-water emulsions
|
JP2002507387A
(ja)
|
1997-12-24 |
2002-03-12 |
コリクサ コーポレイション |
乳癌の免疫療法および診断のための化合物ならびにそれらの使用のための方法
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AR020318A1
(es)
|
1998-03-18 |
2002-05-08 |
Corixa Corp |
Una molecula polinucleotidica aislada, un polipeptido aislado codificado por dicha molecula, un vector de expresion, una celula huesped transformada, unaproteina de fusion, una composicion farmaceutica y una vacuna que comprenden dicho polipeptido o proteina; metodos para el tratamiento, deteccion,
|
JP4227302B2
(ja)
|
1998-04-07 |
2009-02-18 |
コリクサ コーポレイション |
Mycobacteriumtuberculosis抗原の融合タンパク質およびその使用
|
AU3555599A
(en)
|
1998-04-13 |
1999-11-01 |
Luminex Corporation |
Liquid labeling with fluorescent microparticles
|
SE9801288D0
(sv)
|
1998-04-14 |
1998-04-14 |
Astra Ab |
Vaccine delivery system and metod of production
|
GB9810236D0
(en)
|
1998-05-13 |
1998-07-08 |
Microbiological Res Authority |
Improvements relating to encapsulation of bioactive agents
|
US6406719B1
(en)
|
1998-05-13 |
2002-06-18 |
Microbiological Research Authority |
Encapsulation of bioactive agents
|
EP1077722B1
(en)
|
1998-05-22 |
2006-08-09 |
Ottawa Health Research Institute |
Methods and products for inducing mucosal immunity
|
EP1096957A1
(en)
|
1998-06-18 |
2001-05-09 |
Johns Hopkins University School of Medicine |
Methods and reagents for intramuscular delivery of nucleic acids
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
JP2002522451A
(ja)
|
1998-08-07 |
2002-07-23 |
ユニバーシティ オブ ワシントン |
免疫学的単純ヘルペスウイルス抗原とその使用法
|
US6264991B1
(en)
|
1998-08-18 |
2001-07-24 |
Southern Research Institute |
Compositions and methods for treating intracellular infections
|
US6956021B1
(en)
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US7087236B1
(en)
*
|
1998-09-01 |
2006-08-08 |
Merrion Research I Limited |
Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
|
JP4601823B2
(ja)
|
1998-09-01 |
2010-12-22 |
メリオン リサーチ スリー リミテッド |
経口ワクチン組成物
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
FR2786098B1
(fr)
|
1998-11-20 |
2003-05-30 |
Flamel Tech Sa |
Particules a base de polyaminoacide(s) et susceptibles d'etre utilisees comme vecteurs de principe(s) actif(s), suspension colloidale les comprenant et leurs procedes de fabrication
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
WO2000034483A2
(en)
|
1998-12-08 |
2000-06-15 |
Corixa Corporation |
Compounds and methods for treatment and diagnosis of chlamydial infection
|
US20020119158A1
(en)
|
1998-12-17 |
2002-08-29 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of ovarian cancer
|
US6579973B1
(en)
|
1998-12-28 |
2003-06-17 |
Corixa Corporation |
Compositions for the treatment and diagnosis of breast cancer and methods for their use
|
JP2002536966A
(ja)
|
1998-12-30 |
2002-11-05 |
ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド |
カルシウムチャネルファミリーの特徴付け
|
US6395714B1
(en)
|
1999-02-24 |
2002-05-28 |
Aventis Pasteur Limited |
Expressing gp140 fragment of primary HIV-1 isolate
|
EP1169347B1
(en)
|
1999-04-02 |
2008-07-02 |
Corixa Corporation |
Compounds and methods for therapy and diagnosis of lung cancer
|
US20050158856A1
(en)
*
|
1999-04-20 |
2005-07-21 |
Edelson Richard L. |
Methods for producing functional antigen presenting dendritic cells using biodegradable microparticles for delivery of antigenic materials
|
US6521431B1
(en)
|
1999-06-22 |
2003-02-18 |
Access Pharmaceuticals, Inc. |
Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
JP4210454B2
(ja)
*
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
US20020009466A1
(en)
*
|
1999-08-31 |
2002-01-24 |
David J. Brayden |
Oral vaccine compositions
|
ES2592507T3
(es)
|
1999-09-03 |
2016-11-30 |
The Brigham And Women's Hospital, Inc. |
Métodos y composiciones para el tratamiento de enfermedad inflamatoria mediante el uso de agentes moduladores de cadherina-11
|
US6811783B1
(en)
|
1999-09-07 |
2004-11-02 |
Aventis Pasteur Limited |
Immunogenic compositions for protection against chlamydial infection
|
US20050100928A1
(en)
*
|
1999-09-16 |
2005-05-12 |
Zycos Inc., A Delaware Corporation |
Nucleic acids encoding polyepitope polypeptides
|
US6458387B1
(en)
*
|
1999-10-18 |
2002-10-01 |
Epic Therapeutics, Inc. |
Sustained release microspheres
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
FR2801226B1
(fr)
|
1999-11-23 |
2002-01-25 |
Flamel Tech Sa |
Suspension colloidale de particules submicroniques de vectorisation de principes actifs et son mode de preparation
|
AU2001256156B2
(en)
|
2000-02-23 |
2006-01-05 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US20030060487A1
(en)
*
|
2000-04-12 |
2003-03-27 |
Bamdad R. Shoshana |
Treatment of neurodegenerative disease
|
DE60133190T2
(de)
|
2000-04-21 |
2009-04-02 |
CORIXA CORP., Wilmington |
Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
EP1280521B1
(en)
|
2000-05-12 |
2005-07-20 |
Pharmacia & Upjohn Company LLC |
Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
|
JP2003535122A
(ja)
*
|
2000-06-02 |
2003-11-25 |
ザイコス インク. |
生物活性物質のための送達システム
|
FR2814952B1
(fr)
|
2000-10-06 |
2004-01-02 |
Flamel Tech Sa |
Suspension colloidale de particules submicromiques de vectorisation de principes actifs et leur mode de preparation
|
DE60139963D1
(de)
|
2000-06-20 |
2009-10-29 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
ATE440618T1
(de)
|
2000-06-22 |
2009-09-15 |
Univ Iowa Res Found |
Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
US6565888B1
(en)
|
2000-08-23 |
2003-05-20 |
Alkermes Controlled Therapeutics, Inc. |
Methods and compositions for the targeted delivery of biologically active agents
|
US6797704B2
(en)
|
2000-10-06 |
2004-09-28 |
The Johns Hopkins University |
Systemic delivery of compounds through non-invasive bladder administration
|
WO2002043580A2
(en)
|
2000-10-27 |
2002-06-06 |
Epic Therapeutics, Inc. |
Production of microspheres
|
JP4564714B2
(ja)
|
2000-11-27 |
2010-10-20 |
ミナーヴァ・バイオテクノロジーズ・コーポレーション |
診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
|
ATE398175T1
(de)
|
2000-12-08 |
2008-07-15 |
Coley Pharmaceuticals Gmbh |
Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
|
US20030125236A1
(en)
*
|
2000-12-29 |
2003-07-03 |
Advenced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
EP1345629A2
(en)
*
|
2000-12-29 |
2003-09-24 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having sustained release properties
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
MXPA03006358A
(es)
|
2001-01-17 |
2004-12-02 |
Trubion Pharmaceuticals Inc |
Proteinas de fusion dominio de enlace-inmunoglobulina.
|
US7491394B2
(en)
|
2001-02-15 |
2009-02-17 |
The Board Of Trustees Of The University Of Illinois |
Cytotoxic factors for modulating cell death
|
US7618939B2
(en)
*
|
2001-02-15 |
2009-11-17 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to prevent cancer with cupredoxins
|
EP1988097A1
(en)
|
2001-05-09 |
2008-11-05 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
AU2002354644C1
(en)
|
2001-07-10 |
2009-04-30 |
Corixa Corporation |
Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
|
US6746635B2
(en)
*
|
2001-08-08 |
2004-06-08 |
Brown University Research Foundation |
Methods for micronization of hydrophobic drugs
|
ES2307779T3
(es)
*
|
2001-08-16 |
2008-12-01 |
Baxter International Inc. |
Formulaciones de microparticulas a base de propelentes.
|
AU2002346960A1
(en)
|
2001-10-06 |
2003-04-22 |
Merial Limited |
Methods and compositions for promoting growth and innate immunity in young animals
|
EP1578771B1
(en)
|
2001-10-10 |
2013-03-06 |
Novo Nordisk A/S |
Remodeling and glycoconjugation of peptides
|
US20030125292A1
(en)
*
|
2001-11-07 |
2003-07-03 |
Sean Semple |
Mucoscal vaccine and methods for using the same
|
WO2003072016A2
(en)
|
2001-11-19 |
2003-09-04 |
Becton, Dickinson And Company |
Pharmaceutical compositions in particulate form
|
US20030129250A1
(en)
*
|
2001-11-20 |
2003-07-10 |
Advanced Inhalation Research Inc. |
Particulate compositions for improving solubility of poorly soluble agents
|
AU2002352836B2
(en)
|
2001-11-20 |
2005-09-29 |
Alkermes, Inc. |
Improved particulate compositions for pulmonary delivery
|
WO2003049701A2
(en)
*
|
2001-12-10 |
2003-06-19 |
Spherics, Inc. |
Methods and products useful in the formation and isolation of microparticles
|
PT1461054E
(pt)
|
2001-12-11 |
2010-08-09 |
Pasteur Institut |
Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária
|
EP2224012B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
DK1458360T3
(da)
|
2001-12-19 |
2011-08-29 |
Novartis Ag |
Pulmonær afgivelse af aminoglycosider
|
WO2003078448A1
(en)
|
2002-03-13 |
2003-09-25 |
Signum Biosciences, Inc. |
Modulation of protein methylation and phosphoprotein phosphate
|
NZ573064A
(en)
|
2002-04-04 |
2011-02-25 |
Coley Pharm Gmbh |
Immunostimulatory G,U-containing oligoribonucleotides
|
CA2480826C
(fr)
|
2002-04-09 |
2012-02-07 |
Flamel Technologies |
Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
|
HUE039881T2
(hu)
|
2002-05-09 |
2019-02-28 |
Brigham & Womens Hospital Inc |
1L1RL-1, mint egy kardiovaszkuláris betegség-marker
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
FR2840614B1
(fr)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
|
CA2492598C
(en)
|
2002-07-18 |
2013-12-17 |
University Of Washington |
Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
|
WO2004035028A1
(fr)
*
|
2002-10-17 |
2004-04-29 |
Gosudarstvenny Nauchny Tsentr Virusologii I Biotekhnologii 'vektor' |
Procede de production d'une forme microencapsulee d'un vaccin viral vivant
|
JP2006503914A
(ja)
*
|
2002-10-21 |
2006-02-02 |
エムジーアイ ファーマ バイオロジックス インコーポレイテッド |
ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
|
EP1556077A2
(en)
|
2002-10-29 |
2005-07-27 |
Coley Pharmaceutical Group, Ltd |
Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
|
EP1660535A2
(en)
|
2002-11-27 |
2006-05-31 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
AU2004210936C1
(en)
|
2003-02-11 |
2010-12-02 |
Takeda Pharmaceutical Company Limited |
Diagnosis and treatment of Multiple Sulfatase Deficiency and other using a Formylglycine Generating Enzyme (FGE)
|
ES2439580T5
(en)
|
2003-02-28 |
2025-01-23 |
Univ Johns Hopkins |
T cell regulation
|
WO2004078943A2
(en)
*
|
2003-03-04 |
2004-09-16 |
California Institute Of Technology |
Alternative heterocycles for dna recognition
|
MXPA05009726A
(es)
|
2003-03-14 |
2005-11-04 |
Neose Technologies Inc |
Polimeros ramificados, solubles en agua y sus conjugados.
|
US20070026485A1
(en)
|
2003-04-09 |
2007-02-01 |
Neose Technologies, Inc. |
Glycopegylation methods and proteins/peptides produced by the methods
|
EP2377528B1
(en)
|
2003-06-12 |
2014-02-19 |
The Board of Regents of the University of Colorado |
Fatty acid metabolism inhibitors for use in the treatment of cancer
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
DE10329087B4
(de)
*
|
2003-06-27 |
2014-02-13 |
Biomedical International R + D Gmbh |
Antigenhaltige Mikrosphären zur Allergietherapie
|
US8075919B2
(en)
*
|
2003-07-18 |
2011-12-13 |
Baxter International Inc. |
Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
|
US20050142205A1
(en)
*
|
2003-07-18 |
2005-06-30 |
Julia Rashba-Step |
Methods for encapsulating small spherical particles prepared by controlled phase separation
|
US20070092452A1
(en)
*
|
2003-07-18 |
2007-04-26 |
Julia Rashba-Step |
Methods for fabrication, uses, compositions of inhalable spherical particles
|
US20050048127A1
(en)
*
|
2003-07-22 |
2005-03-03 |
Larry Brown |
Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
|
US7663017B2
(en)
|
2003-07-30 |
2010-02-16 |
Institut Pasteur |
Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
|
JP2007502991A
(ja)
|
2003-08-20 |
2007-02-15 |
バイオサイト インコーポレイテッド |
生物活性ナトリウム利尿ペプチドを測定するための、およびその治療可能性を向上させるための方法および組成物
|
US20060173171A1
(en)
*
|
2003-08-26 |
2006-08-03 |
Bamdad Cynthia C |
Techniques and compositions for diagnosis and treatment of cancer (muci)
|
JP2007509040A
(ja)
*
|
2003-10-11 |
2007-04-12 |
イネックス ファーマシューティカルズ コーポレイション |
先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
|
JP5060134B2
(ja)
|
2003-12-12 |
2012-10-31 |
ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
|
EP2248895B8
(en)
|
2003-12-19 |
2016-09-21 |
Autotelic LLC |
Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
|
US7452730B2
(en)
*
|
2004-01-16 |
2008-11-18 |
California Institute Of Technology |
DNA-binding polymers
|
EP1568383A3
(en)
|
2004-02-27 |
2005-11-16 |
Antisense Pharma GmbH |
Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
|
EP1722823A2
(en)
*
|
2004-02-27 |
2006-11-22 |
Antisense Pharma GmbH |
Pharmaceutical composition
|
US7063151B2
(en)
*
|
2004-03-05 |
2006-06-20 |
Halliburton Energy Services, Inc. |
Methods of preparing and using coated particulates
|
ES2415358T3
(es)
|
2004-04-21 |
2013-07-25 |
The Brigham And Women's Hospital, Inc. |
Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
|
US20050239723A1
(en)
*
|
2004-04-27 |
2005-10-27 |
Amin Avinash N |
Compositions and methods useful for treatment of acne
|
US8728525B2
(en)
|
2004-05-12 |
2014-05-20 |
Baxter International Inc. |
Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
|
AU2005244851B2
(en)
|
2004-05-12 |
2010-08-26 |
Baxter Healthcare S.A. |
Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
|
AU2005244842B2
(en)
|
2004-05-12 |
2010-09-23 |
Baxter Healthcare S.A. |
Nucleic acid microspheres, production and delivery thereof
|
JP5634009B2
(ja)
*
|
2004-05-12 |
2014-12-03 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
|
CA2837748C
(en)
|
2004-05-25 |
2016-03-08 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
US20060264411A1
(en)
*
|
2005-05-20 |
2006-11-23 |
Eldridge Gary R |
Control of biofilm formation
|
US7604978B2
(en)
*
|
2004-07-14 |
2009-10-20 |
Sequoia Sciences, Inc. |
Inhibition of biofilm formation
|
DK2199801T3
(da)
|
2004-07-14 |
2013-08-05 |
Univ California |
Biomarkører til tidlig påvisning af ovariecancer
|
US20060014285A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Eldridge Gary R |
Methods and compositions for inhibiting biofilms
|
EP1773766B1
(en)
|
2004-07-15 |
2014-04-02 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
CA2575663C
(en)
|
2004-07-30 |
2013-04-23 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
US9132116B2
(en)
|
2004-08-02 |
2015-09-15 |
Willowcroft Pharm Inc. |
Mast cell stabilizers to prevent or treat laminitis
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
EP2298897B1
(en)
*
|
2004-09-02 |
2013-08-14 |
Yale University |
Regulation of oncogenes by microRNAs
|
EP1811844A4
(en)
*
|
2004-09-14 |
2009-12-02 |
Minerva Biotechnologies Corp |
METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
|
WO2006031943A1
(en)
|
2004-09-14 |
2006-03-23 |
Eldridge Gary R |
Compounds, compositions and methods for controlling biofilms and bacterial infections
|
RU2419628C2
(ru)
*
|
2004-09-22 |
2011-05-27 |
ГлаксоСмитКлайн Байолоджикалз с.а. |
Иммуногенная композиция для применения в вакцинации против стафилококков
|
US20080138847A1
(en)
*
|
2004-09-23 |
2008-06-12 |
Yigong Shi |
Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
|
EP1809759B1
(en)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
US8846051B2
(en)
|
2004-10-08 |
2014-09-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by deoptimization of synonymous codons
|
WO2007001448A2
(en)
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
US20060153786A1
(en)
|
2004-12-10 |
2006-07-13 |
Talima Therapeutics, Inc. |
Compositions and methods for treating conditions of the nail unit
|
US20060275230A1
(en)
|
2004-12-10 |
2006-12-07 |
Frank Kochinke |
Compositions and methods for treating conditions of the nail unit
|
US8137907B2
(en)
*
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
CA2601777A1
(en)
|
2005-02-03 |
2006-08-10 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
WO2006091459A2
(en)
*
|
2005-02-24 |
2006-08-31 |
Joslin Diabetes Center, Inc. |
Compositions and methods for treating vascular permeability
|
JP5198880B2
(ja)
|
2005-02-25 |
2013-05-15 |
テトラロジック ファーマシューティカルズ コーポレーション |
二量体iap阻害剤
|
EP1701165A1
(en)
|
2005-03-07 |
2006-09-13 |
Johannes Dr. Coy |
Therapeutic and diagnostic uses of TKTL1 and inhibitors and activators thereof
|
US7851189B2
(en)
*
|
2005-03-07 |
2010-12-14 |
Boston Scientific Scimed, Inc. |
Microencapsulated compositions for endoluminal tissue engineering
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
EP2526957A3
(en)
|
2005-03-30 |
2013-02-20 |
Minerva Biotechnologies Corporation |
Proliferation of MUC1 expressing cells
|
US20090022755A1
(en)
|
2005-03-31 |
2009-01-22 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
US20060228384A1
(en)
*
|
2005-04-06 |
2006-10-12 |
Sequoia Sciences, Inc. |
Control of biofilm with a biofilm inhibitor
|
WO2006121569A2
(en)
|
2005-04-08 |
2006-11-16 |
Neose Technologies, Inc. |
Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
|
JP2008539169A
(ja)
|
2005-04-19 |
2008-11-13 |
イーライ リリー アンド カンパニー |
疾患における免疫学的介入のための一価および多価合成多糖類抗原
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
EP1877426B1
(en)
|
2005-04-29 |
2012-02-01 |
GlaxoSmithKline Biologicals SA |
Method for preventing or treating m tuberculosis infection
|
PL1877070T3
(pl)
|
2005-05-05 |
2009-06-30 |
Antisense Pharma Gmbh |
Zastosowanie terapeutyczne TGF-beta2 antysensownych oligonukleotydów
|
US20080193543A1
(en)
*
|
2005-05-17 |
2008-08-14 |
Brown University Research Foundation |
Drug Delivery Formulations For Targeted Delivery
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
EP1910410B1
(en)
|
2005-07-01 |
2011-10-26 |
Forsyth Dental Infirmary for Children |
Tuberculosis antigen detection assays and vaccines
|
US20070014739A1
(en)
*
|
2005-07-14 |
2007-01-18 |
Eldridge Gary R |
Compositions and methods for controlling biofilms and bacterial infections
|
US7462698B2
(en)
*
|
2005-07-22 |
2008-12-09 |
Y's Therapeutics Co., Ltd. |
Anti-CD26 antibodies and methods of use thereof
|
PL1912675T3
(pl)
|
2005-07-25 |
2014-10-31 |
Emergent Product Dev Seattle |
Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
US20070042428A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Stacy Springs |
Treatment of proliferative disorders
|
TWI404537B
(zh)
|
2005-08-19 |
2013-08-11 |
Array Biopharma Inc |
作為類鐸受體(toll-like receptor)調節劑之8-經取代苯并氮雜呯
|
WO2007027559A2
(en)
|
2005-08-29 |
2007-03-08 |
Shashoua Victor E |
Neuroprotective and neurorestorative methods and compositions
|
US20080021198A1
(en)
*
|
2005-10-12 |
2008-01-24 |
Yigong Shi |
Modulators of protein phosphatase 2A and PP2A methyl esterase
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
CN102517292B
(zh)
|
2005-11-25 |
2014-12-24 |
佐蒂斯比利时股份有限公司 |
免疫刺激性寡核糖核苷酸
|
US20080280834A1
(en)
*
|
2005-12-01 |
2008-11-13 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Compounds and methods for inhibiting apoptosis
|
WO2007070682A2
(en)
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
WO2007079755A1
(en)
*
|
2006-01-12 |
2007-07-19 |
Janus Beierholm Holding Aps |
Reimmunization and antibody design
|
EP1981905B1
(en)
|
2006-01-16 |
2016-08-31 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Chlamydia vaccine
|
US8921050B2
(en)
|
2006-03-17 |
2014-12-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of diagnosing renal cell carcinoma
|
CA2648099C
(en)
|
2006-03-31 |
2012-05-29 |
The Brigham And Women's Hospital, Inc |
System for targeted delivery of therapeutic agents
|
CA2648718A1
(en)
|
2006-04-07 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
|
DK2027158T3
(da)
|
2006-05-02 |
2013-01-14 |
Carviar Aps |
Metode til immunisering af en fugleart
|
US10522240B2
(en)
|
2006-05-03 |
2019-12-31 |
Population Bio, Inc. |
Evaluating genetic disorders
|
US7702468B2
(en)
|
2006-05-03 |
2010-04-20 |
Population Diagnostics, Inc. |
Evaluating genetic disorders
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
MX2008016036A
(es)
|
2006-06-20 |
2009-04-07 |
Transgene Sa |
Vacuna viral recombinante.
|
US9381477B2
(en)
|
2006-06-23 |
2016-07-05 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
EP2049524A2
(en)
*
|
2006-07-24 |
2009-04-22 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
US20100113326A1
(en)
*
|
2006-07-24 |
2010-05-06 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
CL2007002167A1
(es)
*
|
2006-07-24 |
2009-01-23 |
Tetralogic Pharm Corp |
Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
|
WO2008014236A1
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
EP2647712A3
(en)
|
2006-08-04 |
2013-11-20 |
Baxter International Inc |
Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
|
US20080153773A1
(en)
*
|
2006-08-08 |
2008-06-26 |
Yigong Shi |
Modulators of phosphotyrosyl phosphatase activator
|
EP3795173A1
(en)
|
2006-09-26 |
2021-03-24 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
WO2008147426A2
(en)
*
|
2006-10-04 |
2008-12-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for immunomodulation
|
RU2460543C2
(ru)
|
2006-10-04 |
2012-09-10 |
Ново Нордиск А/С |
Глицерин-связанные пэгилированные сахара и гликопептиды
|
US20100092480A1
(en)
*
|
2006-10-13 |
2010-04-15 |
The Trustees Of The University Of Princeton |
Modulators of protein phosphatase 2a
|
RU2373957C2
(ru)
|
2006-10-13 |
2009-11-27 |
Александр Метталинович Тишин |
Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
US8202967B2
(en)
|
2006-10-27 |
2012-06-19 |
Boehringer Ingelheim Vetmedica, Inc. |
H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
|
WO2008098165A2
(en)
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
US20100119474A1
(en)
*
|
2007-03-06 |
2010-05-13 |
Cornell University |
Chronic obstructive pulmonary disease susceptibility and related compositions and methods
|
WO2008116216A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for inhibiting cancer metastasis
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
US20090074828A1
(en)
|
2007-04-04 |
2009-03-19 |
Massachusetts Institute Of Technology |
Poly(amino acid) targeting moieties
|
DK2644205T3
(en)
|
2007-04-12 |
2018-09-24 |
Brigham & Womens Hospital Inc |
Targeting ABCB5 for Cancer Therapy
|
AU2008242842B2
(en)
|
2007-04-17 |
2014-06-05 |
Baxter Healthcare Sa |
Nucleic acid microparticles for pulmonary delivery
|
WO2008130619A2
(en)
*
|
2007-04-20 |
2008-10-30 |
Trustees Of Boston College |
A composition comprising an inhibitor of pde4 and/or pde7
|
US8747872B2
(en)
*
|
2007-05-02 |
2014-06-10 |
The Regents Of The University Of Michigan |
Nanoemulsion therapeutic compositions and methods of using the same
|
AU2008252577A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Class A oligonucleotides with immunostimulatory potency
|
JP2010532749A
(ja)
*
|
2007-06-07 |
2010-10-14 |
サーモディクス ファーマシューティカルズ, インコーポレイテッド |
質量を削減した長時間作用剤形
|
CN103602724B
(zh)
|
2007-06-08 |
2016-03-16 |
由卫生与公众服务部代表的美利坚合众国政府 |
确定肝细胞癌亚型和检测肝癌干细胞的方法
|
EP2591787A1
(en)
|
2007-08-13 |
2013-05-15 |
Pfizer Inc |
Combination motif immune stimulatory oligonucleotides with improved activity
|
US8932558B2
(en)
*
|
2007-10-05 |
2015-01-13 |
Plaxgen Inc |
Multi-subunit biological complexes for treatment of plaque-associated diseases
|
ES2627233T3
(es)
|
2007-10-12 |
2017-07-27 |
Massachusetts Institute Of Technology |
Nanotecnología de vacunas
|
US8619257B2
(en)
|
2007-12-13 |
2013-12-31 |
Kimberley-Clark Worldwide, Inc. |
Recombinant bacteriophage for detection of nosocomial infection
|
US20090274682A1
(en)
*
|
2008-02-05 |
2009-11-05 |
The Trustees Of Princeton University |
Demethylation and inactivation of protein phosphatase 2a
|
US20090233858A1
(en)
*
|
2008-02-26 |
2009-09-17 |
The Trustees Of Princeton University |
Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
|
CA2717169A1
(en)
*
|
2008-03-01 |
2009-09-17 |
Abraxis Bioscience, Llc |
Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
|
WO2009126306A2
(en)
|
2008-04-10 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
JP2011522515A
(ja)
|
2008-04-10 |
2011-08-04 |
マサチューセッツ インスティテュート オブ テクノロジー |
癌幹細胞を標的とする薬剤を同定する方法およびその使用
|
HRP20110619T1
(hr)
|
2008-04-11 |
2011-09-30 |
Emergent Product Development Seattle |
Cd37 imunoterapeutik i njegova kombinacija s bifunkcionalnim kemoterapeutikom
|
CN102007213B
(zh)
|
2008-04-18 |
2014-08-06 |
巴克斯特国际公司 |
用于预防和/或逆转新发作的自身免疫性糖尿病的基于微球的组合物
|
US20100227853A1
(en)
*
|
2008-04-18 |
2010-09-09 |
Trustees Of Boston College |
Inhibitors of cyclic amp phosphodiesterases
|
AU2009239655B2
(en)
|
2008-04-25 |
2014-05-22 |
Innate Pharma |
Improved TLR3 agonist compositions
|
CN102076853A
(zh)
*
|
2008-05-07 |
2011-05-25 |
阿布拉西斯生物科学有限责任公司 |
通过miRNA增强药物疗法
|
EP2123748A1
(en)
|
2008-05-20 |
2009-11-25 |
Institut Pasteur |
2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
|
EP2303888B1
(en)
|
2008-06-12 |
2015-05-06 |
President and Fellows of Harvard College |
Compounds for antimicrobial intervention
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
WO2010011347A2
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
WO2010017103A2
(en)
*
|
2008-08-04 |
2010-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic |
Fully human anti-human nkg2d monoclonal antibodies
|
US8323615B2
(en)
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing multi-phasic dispersions
|
US8367427B2
(en)
|
2008-08-20 |
2013-02-05 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
US8323685B2
(en)
*
|
2008-08-20 |
2012-12-04 |
Baxter International Inc. |
Methods of processing compositions containing microparticles
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
EP2331103A1
(en)
*
|
2008-09-22 |
2011-06-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Nuclear factor kappa b pathway inhibitor composition and use of same
|
CA2740087C
(en)
*
|
2008-10-08 |
2019-07-23 |
Kyphia Pharmaceuticals, Inc. |
Gaba conjugates and methods of use thereof
|
EP4201421A1
(en)
|
2008-10-09 |
2023-06-28 |
Minerva Biotechnologies Corporation |
Method for inducing pluripotency in cells
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
EP3978928A1
(en)
|
2008-11-14 |
2022-04-06 |
The Brigham and Women's Hospital, Inc. |
Therapeutic and diagnostic methods relating to cancer stem cells
|
EP2376089B1
(en)
|
2008-11-17 |
2018-03-14 |
The Regents of the University of Michigan |
Cancer vaccine compositions and methods of using the same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
EP2418945B1
(en)
|
2009-04-15 |
2018-12-05 |
BMG PHARMA S.p.A. |
Mineral salt-sulfonic acid compositions and methods of use
|
US9316646B2
(en)
|
2009-04-23 |
2016-04-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ROR1 antibodies
|
WO2010127235A1
(en)
|
2009-04-30 |
2010-11-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Schweinfurthins and uses thereof
|
PL2429581T3
(pl)
|
2009-05-14 |
2016-01-29 |
Bayer Ip Gmbh |
Wzmocniona odpowiedź immunologiczna u gatunków ptaków
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
HUE031051T2
(en)
|
2009-06-05 |
2017-06-28 |
Infectious Disease Res Inst |
Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
|
WO2010144611A2
(en)
*
|
2009-06-10 |
2010-12-16 |
3-V Biosciences, Inc. |
Antivirals that target transporters, carriers, and ion channels
|
IN2012DN00352A
(h)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
EP3020412B1
(en)
|
2009-06-16 |
2017-10-11 |
The Regents of the University of Michigan |
An immunogenic composition comprising nanoemulsion inactivated rsv
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
US9089573B2
(en)
|
2009-07-22 |
2015-07-28 |
University Of Massachusetts |
Methods and compositions to reduce oxidative stress
|
RU2012107535A
(ru)
|
2009-07-30 |
2013-09-10 |
Антисенс Фарма Гмбх |
КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
|
EP2292260A1
(en)
|
2009-08-13 |
2011-03-09 |
Institut Pasteur |
Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
|
EP2287304A1
(en)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
|
PL2467377T3
(pl)
|
2009-08-18 |
2017-10-31 |
Ventirx Pharmaceuticals Inc |
Podstawione benzoazepiny jako modulatory receptora toll-podobnego
|
HRP20170268T1
(hr)
|
2009-08-18 |
2017-05-19 |
Ventirx Pharmaceuticals, Inc. |
Supstituirani benzodiazepeni kao modulatori receptora sličnih tollu
|
DK2477652T3
(en)
|
2009-09-16 |
2015-07-20 |
Vaxart Inc |
Immunization strategy for the prevention of infection H1Ni
|
US8465743B2
(en)
|
2009-10-01 |
2013-06-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
US20110104138A1
(en)
|
2009-11-03 |
2011-05-05 |
Institut Pasteur |
Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
|
EP3461889B1
(en)
|
2009-11-19 |
2025-01-29 |
Solis BioDyne OÜ |
Compositions for increasing polypeptide stability and activity, and related methods
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
AU2011206761A1
(en)
|
2010-01-13 |
2012-07-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti - infective pyrido (1,2 -a) pyrimidines
|
WO2011092253A1
(en)
|
2010-01-27 |
2011-08-04 |
Glaxosmithkline Biologicals S.A. |
Modified tuberculosis antigens
|
WO2011116396A2
(en)
|
2010-03-19 |
2011-09-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
US20110293585A1
(en)
|
2010-04-21 |
2011-12-01 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
WO2011133803A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
EP2566967B1
(en)
|
2010-05-04 |
2016-07-06 |
The Brigham and Women's Hospital, Inc. |
Cadherin-11 antagonist for the treatment of fibrosis
|
WO2011138032A2
(en)
|
2010-05-05 |
2011-11-10 |
Artemev, Timur |
Universal influenza vaccines and methods for their generation
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
WO2012012627A1
(en)
|
2010-07-22 |
2012-01-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of preventing or treating viral infection
|
US8862410B2
(en)
|
2010-08-02 |
2014-10-14 |
Population Diagnostics, Inc. |
Compositions and methods for discovery of causative mutations in genetic disorders
|
AR083533A1
(es)
|
2010-10-22 |
2013-03-06 |
Boehringer Ingelheim Vetmed |
Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
|
CN108744262A
(zh)
|
2010-11-23 |
2018-11-06 |
普莱萨格生命科学公司 |
用于实体递送的治疗方法和组合物
|
ES2657970T3
(es)
|
2010-12-01 |
2018-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos contra ROR1 de conejo/ser humano quiméricos
|
UA118537C2
(uk)
|
2010-12-22 |
2019-02-11 |
Байєр Інтеллектуал Проперті Гмбх |
Композиція імуномодулятора для лікування респіратоного захворювання у великої рогатої худоби
|
CN103562201B
(zh)
|
2011-01-12 |
2016-10-19 |
帆德制药股份有限公司 |
作为toll样受体调节剂的取代的苯并氮杂卓
|
EP2663550B1
(en)
|
2011-01-12 |
2016-12-14 |
VentiRx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
EP2670850B1
(en)
|
2011-02-03 |
2016-10-26 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
CA2826043A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
MX342287B
(es)
|
2011-03-08 |
2016-09-23 |
3-V Biosciences Inc |
Moduladores heterociclicos de sintesis lipidica.
|
CN108220297A
(zh)
|
2011-03-09 |
2018-06-29 |
细胞信号科技公司 |
用于生成单克隆抗体的方法和试剂
|
WO2012126013A2
(en)
|
2011-03-17 |
2012-09-20 |
Minerva Biotechnologies Corporation |
Method for making pluripotent stem cells
|
WO2012138475A1
(en)
|
2011-04-08 |
2012-10-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
BR112013025799A2
(pt)
|
2011-04-08 |
2016-12-20 |
Immune Design Corp |
método para induzir uma resposta imune em um sujeito, e, preparação
|
WO2012145739A1
(en)
|
2011-04-21 |
2012-10-26 |
Trustees Of Tufts College |
Compositions and methods for stabilization of active agents
|
WO2012167053A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
JP6093759B2
(ja)
|
2011-06-01 |
2017-03-08 |
ジャナス バイオセラピューティクス,インク. |
新規の免疫系調節剤
|
BR112013032199A2
(pt)
|
2011-06-14 |
2017-12-12 |
Bikam Pharmaceuticals Inc |
ligantes de ligação à opsina, composições e métodos de utilização
|
WO2012174455A2
(en)
|
2011-06-17 |
2012-12-20 |
University Of Tennessee Research Foundation |
Group a streptococcus multivalent vaccine
|
EP2723365A1
(en)
|
2011-06-21 |
2014-04-30 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
SG10201608671SA
(en)
|
2011-07-18 |
2016-12-29 |
Harvard College |
Engineered Microbe-Targeting Molecules and Uses Thereof
|
WO2013013061A1
(en)
|
2011-07-19 |
2013-01-24 |
University Of Vermont And State Agricultural College |
Methods and compounds for treating cancer
|
US8324264B1
(en)
|
2011-07-22 |
2012-12-04 |
Sequoia Sciences, Inc. |
Inhibitors of bacterial biofilms and related methods
|
CA2844197A1
(en)
|
2011-08-03 |
2013-02-07 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolina Healthcare System |
Treatment of fibrosis using microrna-19b
|
AR088028A1
(es)
|
2011-08-15 |
2014-05-07 |
Boehringer Ingelheim Vetmed |
Proteinas h5, de h5n1 para un uso medicinal
|
IN2014KN00948A
(h)
|
2011-10-04 |
2015-08-21 |
Janus Biotherapeutics Inc |
|
CA2851388C
(en)
|
2011-10-10 |
2023-11-21 |
The Hospital For Sick Children |
Methods and compositions for screening and treating developmental disorders
|
EP2768945B1
(en)
|
2011-10-17 |
2022-01-05 |
Minerva Biotechnologies Corporation |
Media for stem cell proliferation and induction
|
BR112014008849A2
(pt)
|
2011-10-20 |
2017-09-12 |
Us Health |
receptores quiméricos de antígeno anti-cd22
|
JP2014534864A
(ja)
|
2011-10-28 |
2014-12-25 |
プレサージュ バイオサイエンシズ,インコーポレイテッド |
薬物デリバリー方法
|
WO2013067451A2
(en)
|
2011-11-04 |
2013-05-10 |
Population Diagnostics Inc. |
Methods and compositions for diagnosing, prognosing, and treating neurological conditions
|
CN107880101B
(zh)
|
2011-11-11 |
2021-12-21 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
WO2013082275A1
(en)
|
2011-11-30 |
2013-06-06 |
Trustees Of Boston College |
Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
PT2811981T
(pt)
|
2012-02-07 |
2019-06-12 |
Infectious Disease Res Inst |
Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
|
EP2812452B1
(en)
|
2012-02-09 |
2020-05-27 |
Population Bio, Inc. |
Methods and compositions for screening and treating developmental disorders
|
CN103251941A
(zh)
*
|
2012-02-16 |
2013-08-21 |
海南大学 |
动物病毒性疫苗脉冲释放系统、其制备方法及用途
|
CN104780932A
(zh)
|
2012-02-29 |
2015-07-15 |
伊西康内外科公司 |
微生物区系的组合物及与其相关的方法
|
WO2013134577A2
(en)
|
2012-03-08 |
2013-09-12 |
Detectogen, Inc. |
Leishmaniasis antigen detection assays and vaccines
|
CA3116051C
(en)
|
2012-03-23 |
2023-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
ES2719495T5
(en)
|
2012-05-07 |
2025-09-10 |
Dartmouth College |
Anti-b7-h6 antibody, fusion proteins, and methods of using the same
|
PT2850431T
(pt)
|
2012-05-16 |
2018-07-23 |
Immune Design Corp |
Vacinas para hsv-2
|
US10583169B2
(en)
|
2012-07-11 |
2020-03-10 |
University Of Vermont And State Agricultural College |
Methylation-controlled J protein (MCJ) for treatment of liver disease and altering mitochondrial metabolism
|
MX356830B
(es)
|
2012-07-13 |
2018-06-15 |
Shin Nippon Biomedical Laboratories Ltd |
Adyuvante de acido nucleico quiral.
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
CA2881818A1
(en)
|
2012-08-21 |
2014-02-27 |
Genesys Research Institute |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
DK2895621T3
(da)
|
2012-09-14 |
2020-11-30 |
Population Bio Inc |
Fremgangsmåder og sammensætning til diagnosticering, prognose og behandling af neurologiske tilstande
|
EP2900835B1
(en)
|
2012-09-27 |
2025-04-30 |
Population Bio, Inc. |
Method for screening and treating developmental disorders
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
EP2904119B1
(en)
|
2012-10-02 |
2020-06-17 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Methods relating to dna-sensing pathway related conditions
|
EP2912061B1
(en)
|
2012-10-24 |
2019-02-06 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
M971 chimeric antigen receptors
|
WO2014074805A1
(en)
|
2012-11-08 |
2014-05-15 |
Whitehead Institute For Biomedical Research |
Selective targeting of cancer stem cells
|
WO2014093726A1
(en)
|
2012-12-12 |
2014-06-19 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating portal hypertension
|
WO2014093711A1
(en)
|
2012-12-12 |
2014-06-19 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
|
ES2689878T3
(es)
|
2013-02-21 |
2018-11-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
|
CN105377355A
(zh)
|
2013-03-14 |
2016-03-02 |
拇趾公司 |
治疗甲单元的感染、疾病或病症的方法
|
EP3919070B1
(en)
|
2013-03-14 |
2024-10-16 |
Children's Medical Center Corporation |
Use of cd36 to identify cancer subjects for treatment by a psap peptide
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
AU2014233480B2
(en)
|
2013-03-15 |
2018-08-09 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
JP2016522165A
(ja)
|
2013-04-04 |
2016-07-28 |
イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ |
胸腺間質性リンパ球新生因子フラグメント及びその使用
|
KR102039520B1
(ko)
|
2013-04-18 |
2019-11-01 |
이뮨 디자인 코포레이션 |
암 치료에 이용하기 위한 gla 단일요법
|
WO2014182635A1
(en)
|
2013-05-08 |
2014-11-13 |
Baldwin Megan E |
Biomarkers for age-related macular degeneration (amd)
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
MX381320B
(es)
|
2013-06-25 |
2025-03-12 |
Walter & Eliza Hall Inst Medical Res |
Usos de antagonistas de iap en infecciones intracelulares.
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
US10231993B2
(en)
|
2013-06-27 |
2019-03-19 |
University Of Washington Through Its Center For Commercialization |
Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
|
WO2015006543A1
(en)
|
2013-07-10 |
2015-01-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for predicting and detecting tumor metastasis in kidney cancer
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
WO2015013214A2
(en)
|
2013-07-21 |
2015-01-29 |
Whole Biome, Inc. |
Methods and systems for microbiome characterization, monitoring and treatment
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
MX2016005101A
(es)
|
2013-10-21 |
2017-01-09 |
Salk Inst For Biological Studi |
Factor de crecimiento de fibroblastos (fgf) 1 mutado y procedimientos de uso.
|
EP3063171B1
(en)
|
2013-11-01 |
2019-07-24 |
University Of Oslo |
Albumin variants and uses thereof
|
WO2015071763A2
(en)
|
2013-11-15 |
2015-05-21 |
Oslo Universitetssykehus Hf |
Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
|
SG11201604565WA
(en)
|
2013-12-06 |
2016-07-28 |
Us Health |
Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
|
EP3083658B1
(en)
|
2013-12-18 |
2019-05-08 |
President and Fellows of Harvard College |
Crp capture/detection of gram positive bacteria
|
JP6820097B2
(ja)
|
2013-12-20 |
2021-01-27 |
サギメット バイオサイエンシーズ インコーポレイテッド |
脂質合成の複素環式モジュレータ及びその組み合わせ
|
KR102335142B1
(ko)
|
2014-01-07 |
2021-12-06 |
새지메트 바이오사이언시스, 인코포레이티드 |
암 및 바이러스 감염에 대해서 사용하기 위한 지질 합성의 헤테로사이클릭 조절인자
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2935722A1
(en)
|
2014-01-21 |
2015-07-30 |
Immune Design Corp. |
Compositions for use in the treatment of allergic conditions
|
ES2978921T3
(es)
|
2014-02-20 |
2024-09-23 |
Vaxart Inc |
Formulaciones para administración en el intestino delgado
|
CA2940794C
(en)
|
2014-02-28 |
2022-05-31 |
Bayer Animal Health Gmbh |
Immunostimulatory plasmids
|
AU2015229227B2
(en)
|
2014-03-14 |
2021-03-18 |
University Of Washington |
Genomic insulator elements and uses thereof
|
WO2015148801A1
(en)
|
2014-03-26 |
2015-10-01 |
Children's Medical Center Corporation |
Cyclic prosaposin peptides and uses thereof
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
JP6836400B2
(ja)
|
2014-03-28 |
2021-03-03 |
ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション |
乳がんおよび卵巣がんワクチン
|
WO2015168255A1
(en)
|
2014-04-29 |
2015-11-05 |
Whitehead Institute For Biomedical Research |
Methods and compositions for targeting cancer stem cells
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
PL3140269T3
(pl)
|
2014-05-09 |
2024-03-11 |
Yale University |
Cząstki pokryte hiperrozgałęzionym poliglicerolem oraz sposoby ich wytwarzania i zastosowania
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
US11319567B2
(en)
|
2014-05-27 |
2022-05-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7062361B2
(ja)
|
2014-05-27 |
2022-05-06 |
アカデミア シニカ |
抗her2糖操作抗体群およびその使用
|
CA2950433A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
EP3169699A4
(en)
|
2014-07-18 |
2018-06-20 |
The University of Washington |
Cancer vaccine compositions and methods of use thereof
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
GB2558326B
(en)
|
2014-09-05 |
2021-01-20 |
Population Bio Inc |
Methods and compositions for inhibiting and treating neurological conditions
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
CA2961609C
(en)
|
2014-09-17 |
2023-03-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
WO2016054240A1
(en)
|
2014-09-30 |
2016-04-07 |
Sean Dalziel |
Fixed dose combinations for the treatment of viral diseases
|
JP7158853B2
(ja)
|
2014-10-10 |
2022-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
|
CA2964467A1
(en)
|
2014-10-14 |
2016-04-21 |
Research Development Foundation |
Methods for generating engineered enzymes
|
JP6868562B2
(ja)
|
2014-10-31 |
2021-05-19 |
ペンデュラム セラピューティクス, インコーポレイテッド |
障害の微生物的処置および診断に関する方法および組成物
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
AU2016219350A1
(en)
|
2015-02-10 |
2017-08-24 |
Minerva Biotechnologies Corporation |
Humanized anti-MUC1* antibodies
|
US10350262B2
(en)
|
2015-02-18 |
2019-07-16 |
University Of Vermont And State Agricultural College |
MCJ agonists and uses therefor
|
CN107530416A
(zh)
|
2015-03-05 |
2018-01-02 |
西北大学 |
非神经侵染的病毒及其用途
|
CN107428728A
(zh)
|
2015-03-19 |
2017-12-01 |
3-V生物科学股份有限公司 |
脂质合成的杂环调节剂
|
EP3270937A4
(en)
|
2015-03-26 |
2018-09-12 |
The Trustees Of Dartmouth College |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
ES2794628T3
(es)
|
2015-04-15 |
2020-11-18 |
Univ Massachusetts |
Composiciones y métodos para la reactivación de cromosomas XI
|
CN108136021A
(zh)
|
2015-04-25 |
2018-06-08 |
综合医院公司 |
用于治疗癌症的抗驱走性试剂和抗癌剂联合疗法和组合物
|
CN115925878A
(zh)
|
2015-06-05 |
2023-04-07 |
艾比欧公司 |
用于治疗纤维化的内皮抑素片段和变体
|
KR102773575B1
(ko)
|
2015-06-12 |
2025-02-27 |
박사르트, 인크. |
Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
|
EP3831844B1
(en)
|
2015-06-26 |
2024-03-13 |
Prindex S.r.l. |
Diagnosis and therapy of multiple sclerosis
|
JP2018521130A
(ja)
|
2015-07-10 |
2018-08-02 |
ユニバーシティ・オブ・バーモント・アンド・ステイト・アグリカルチュラル・カレッジUniversity Of Vermont And State Agricultural College |
薬物性疾患および状態を治療する方法および組成物
|
TW201718001A
(zh)
|
2015-07-31 |
2017-06-01 |
拜耳動物保健有限公司 |
豬物種中增強之免疫反應
|
US10435457B2
(en)
|
2015-08-06 |
2019-10-08 |
President And Fellows Of Harvard College |
Microbe-binding molecules and uses thereof
|
CA2995079A1
(en)
|
2015-08-20 |
2017-02-23 |
ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE |
Methods and compositions to treat liver diseases and conditions
|
AU2016324144B2
(en)
|
2015-09-17 |
2021-07-29 |
University Of Massachusetts |
Compositions and methods for modulating FMR1 expression
|
JP2018531229A
(ja)
|
2015-09-18 |
2018-10-25 |
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル |
癌の治療のための抗fugetactic剤の局所的送達
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
JP2019507582A
(ja)
|
2015-12-04 |
2019-03-22 |
ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム |
免疫療法用のslc45a2ペプチド
|
KR20180099887A
(ko)
|
2016-01-20 |
2018-09-05 |
더 스크립스 리서치 인스티튜트 |
Ror2 항체 조성물 및 관련 방법
|
CA3011815A1
(en)
|
2016-01-20 |
2017-07-27 |
The Scripps Research Institute |
Ror1 antibody compositions and related methods
|
CA3014792A1
(en)
|
2016-02-16 |
2017-08-24 |
Carnegie Mellon University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
AU2017221424A1
(en)
|
2016-02-16 |
2018-09-20 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
US10336784B2
(en)
|
2016-03-08 |
2019-07-02 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
EP3436066A1
(en)
|
2016-04-01 |
2019-02-06 |
Checkmate Pharmaceuticals, Inc. |
Fc receptor-mediated drug delivery
|
KR102611444B1
(ko)
|
2016-04-08 |
2023-12-06 |
지엘바이오, 인크. |
플렉틴-1 결합 항체 및 그의 용도
|
AU2017259821B2
(en)
|
2016-05-04 |
2024-07-18 |
Abilita Bio, Inc. |
Methods and platform for preparing multispanning membrane proteins
|
WO2017196979A1
(en)
|
2016-05-10 |
2017-11-16 |
The Regents Of The University Of Michigan |
Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
|
IL299285B2
(en)
|
2016-05-16 |
2024-12-01 |
Access To Advanced Health Inst |
Formulation containing tlr agonist and methods of use
|
KR102483033B1
(ko)
|
2016-05-16 |
2022-12-30 |
액세스 투 어드밴스드 헬스 인스티튜트 |
페길화된 리포솜 및 이의 용도
|
CA3025516A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
CN120189506A
(zh)
|
2016-06-01 |
2025-06-24 |
高级健康研究所 |
含上胶剂的纳米明矾颗粒
|
US20190322643A1
(en)
|
2016-06-29 |
2019-10-24 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
SG11201900710YA
(en)
|
2016-07-26 |
2019-02-27 |
Bayer Animal Health Gmbh |
Increased fertility in bovine species
|
EP3500594A4
(en)
|
2016-08-22 |
2020-03-11 |
Cho Pharma Inc. |
ANTIBODIES, BINDING FRAGMENTS AND METHOD FOR USE
|
US11325951B2
(en)
|
2016-09-09 |
2022-05-10 |
The General Hospital Corporation |
HSP fusion protein with anti-chemorepellant agent for treatment of cancer
|
WO2018049120A1
(en)
|
2016-09-09 |
2018-03-15 |
The General Hospital Corporation |
Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer
|
US11453706B2
(en)
|
2016-09-09 |
2022-09-27 |
The General Hospital Corporation |
HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
|
WO2018063472A1
(en)
|
2016-09-27 |
2018-04-05 |
Reyoung Corporation |
Compositions for treating parasitic diseases and methods thereof
|
US11725232B2
(en)
|
2016-10-31 |
2023-08-15 |
The Hong Kong University Of Science And Technology |
Compositions, methods and kits for detection of genetic variants for alzheimer's disease
|
US11160823B2
(en)
|
2016-11-07 |
2021-11-02 |
University Of Massachusetts |
Therapeutic targets for facioscapulohumeral muscular dystrophy
|
WO2018096396A1
(en)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Albumin variants and uses thereof
|
US10240205B2
(en)
|
2017-02-03 |
2019-03-26 |
Population Bio, Inc. |
Methods for assessing risk of developing a viral disease using a genetic test
|
WO2018145109A1
(en)
|
2017-02-06 |
2018-08-09 |
Massachusetts Institute Of Technology |
Methods and products related to glutaminase inhibitors
|
US11260132B2
(en)
|
2017-03-16 |
2022-03-01 |
Children's Medical Center Corporation |
Engineered liposomes as cancer-targeted therapeutics
|
US11547694B2
(en)
|
2017-03-23 |
2023-01-10 |
The General Hospital Corporation |
CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease
|
EP4293129A3
(en)
|
2017-03-27 |
2024-03-06 |
Tenfold Technologies, LLC |
Methods and agricultural compositions for preventing or controlling plant diseases
|
US12274732B2
(en)
|
2017-03-27 |
2025-04-15 |
Tenfold Technologies, LLC |
Anti-pathogen composition and methods of use thereof
|
WO2018187493A1
(en)
|
2017-04-04 |
2018-10-11 |
Yale University |
Compositions and methods for in utero delivery
|
US11225512B2
(en)
|
2017-04-27 |
2022-01-18 |
University Of New Hampshire |
Compositions and methods for ceramide-elevating therapeutic strategies
|
WO2018213612A1
(en)
|
2017-05-18 |
2018-11-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
AU2018283973B2
(en)
|
2017-06-11 |
2025-04-24 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
KR102673794B1
(ko)
|
2017-06-15 |
2024-06-11 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
WO2019009813A2
(en)
|
2017-07-06 |
2019-01-10 |
National University Of Singapore |
METHODS OF INHIBITING CELL PROLIFERATION AND METTL8 ACTIVITY
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
JP2020526537A
(ja)
|
2017-07-14 |
2020-08-31 |
ユニバーシティ オブ マサチューセッツ |
炎症を処置するための方法および組成物
|
EP3655437A1
(en)
|
2017-07-20 |
2020-05-27 |
NBE-Therapeutics AG |
Human antibodies binding to ror2
|
RU2764031C2
(ru)
|
2017-08-07 |
2022-01-12 |
ЭнБиИ - ТЕРАПЬЮТИКС АГ |
Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью
|
AU2018326705A1
(en)
|
2017-08-30 |
2020-03-05 |
Pendulum Therapeutics, Inc. |
Methods and compositions for treatment of microbiome-associated disorders
|
US12005112B2
(en)
|
2017-09-07 |
2024-06-11 |
University Of Oslo |
Vaccine molecules
|
JP2020533338A
(ja)
|
2017-09-07 |
2020-11-19 |
ユニバーシティ オブ オスロUniversity of Oslo |
ワクチン分子
|
WO2019075385A1
(en)
|
2017-10-12 |
2019-04-18 |
Board Of Regents, The University Of Texas System |
T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
|
WO2019108656A1
(en)
|
2017-11-28 |
2019-06-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Microbicidal composition
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
WO2019156565A1
(en)
|
2018-02-12 |
2019-08-15 |
Fast Forward Pharmaceuticals B.V. |
Improved antagonistic anti-human cd40 monoclonal antibodies
|
US12246031B2
(en)
|
2018-02-13 |
2025-03-11 |
Checkmate Pharmaceuticals, Inc. |
Compositions and methods for tumor immunotherapy
|
JP7511478B2
(ja)
|
2018-04-09 |
2024-07-05 |
チェックメイト ファーマシューティカルズ |
ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
|
WO2019204154A1
(en)
|
2018-04-18 |
2019-10-24 |
Reyoung Corporation |
Compositions and methods for treating liver cancer
|
SG11202010347XA
(en)
|
2018-04-19 |
2020-11-27 |
Tvardi Therapeutics Inc |
Stat3 inhibitors
|
WO2019217164A1
(en)
|
2018-05-09 |
2019-11-14 |
Reyoung Corporation |
Compositions and methods for treating cancer and other diseases
|
CA3100276A1
(en)
|
2018-06-06 |
2019-12-12 |
Massachusetts Institute Of Technology |
Circular rna for translation in eukaryotic cells
|
WO2020001657A1
(en)
|
2018-06-29 |
2020-01-02 |
Wuhan Neurophth Biological Technology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
AU2019296451B2
(en)
|
2018-06-29 |
2021-04-29 |
Wuhan Neurophth Biotechnology Limited Company |
Compositions and methods for treating leber's hereditary optic neuropathy
|
EP3823651A4
(en)
|
2018-07-19 |
2022-04-27 |
Pendulum Therapeutics, Inc. |
METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
|
FI3625368T3
(fi)
|
2018-08-08 |
2023-01-13 |
|
Menetelmiä john cunningham -viruksen aiheuttaman progressiivin multifokaalin leukoenkefalopatian kehittymisen riskin arviointiin geneettisellä testauksella
|
CN112584874A
(zh)
|
2018-08-20 |
2021-03-30 |
武汉纽福斯生物科技有限公司 |
用于治疗莱伯氏遗传性视神经病变的组合物和方法
|
WO2020041378A1
(en)
|
2018-08-22 |
2020-02-27 |
Bacainn Therapeutics, Inc. |
Cyclosporine compositions and methods of use
|
CA3111518A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing donor oligonucleotide-based gene editing
|
WO2020047353A1
(en)
|
2018-08-31 |
2020-03-05 |
Yale University |
Compositions and methods for enhancing triplex and nuclease-based gene editing
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
JP2022508619A
(ja)
|
2018-10-04 |
2022-01-19 |
ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー |
ニューロメジンペプチドを使用して2型サイトカイン媒介性炎症を低減させる方法
|
US11266617B2
(en)
|
2018-10-16 |
2022-03-08 |
Massachusetts Institute Of Technology |
Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
|
CN112912497B
(zh)
|
2018-10-19 |
2024-01-12 |
德克萨斯州大学系统董事会 |
工程化长散在元件(line)转座子及其使用方法
|
WO2020102454A1
(en)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Cd40 targeted peptides and uses thereof
|
EP3883562A4
(en)
|
2018-11-21 |
2022-08-03 |
Tremeau Pharmaceuticals, Inc. |
PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
|
EP3677693A1
(en)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimeric gene trancripts (tcgts) as cancer biomarkers
|
MX2021008652A
(es)
|
2019-01-18 |
2021-10-26 |
Janssen Biotech Inc |
Receptores de antígenos quiméricos de gprc5d y células que los expresan.
|
JP2022524289A
(ja)
|
2019-01-30 |
2022-05-02 |
ヤンセン ファーマシューティカ エヌ.ベー. |
分子サブタイプに基づいて前立腺癌を治療する方法
|
US20220054494A1
(en)
|
2019-03-13 |
2022-02-24 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods for treating bladder and urethra dysfunction and disease
|
US20220175934A1
(en)
|
2019-03-21 |
2022-06-09 |
Mitotherapeutix Llc |
Multivalent ligand clusters for targeted delivery of therapeutic agents
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
SG11202112922WA
(en)
|
2019-05-22 |
2021-12-30 |
Massachusetts Inst Technology |
Circular rna compositions and methods
|
WO2020239478A1
(en)
|
2019-05-28 |
2020-12-03 |
Pharma Mar, S.A. |
Trabectedin for treating sarcomas based on genomic markers
|
US20220372474A1
(en)
|
2019-06-21 |
2022-11-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
US20220243211A1
(en)
|
2019-06-21 |
2022-08-04 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
CN114364402A
(zh)
|
2019-07-15 |
2022-04-15 |
罗瓦萨公司 |
用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂,特别是纳洛酮和/或纳曲酮
|
NZ785553A
(en)
|
2019-07-26 |
2025-07-25 |
Janssen Biotech Inc |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
CA3148735A1
(en)
|
2019-07-26 |
2021-02-04 |
Janssen Biotech, Inc. |
Anti-hk2 chimeric antigen receptor (car)
|
WO2021022161A1
(en)
|
2019-07-31 |
2021-02-04 |
Yale University |
Compositions and methods for treating sickle cell disease
|
MX2022001732A
(es)
|
2019-08-12 |
2022-05-06 |
Purinomia Biotech Inc |
Metodos y composiciones para promover y potenciar la respuesta inmunitaria mediada por linfocitos t dirigida a la adcc de las celulas con expresion de cd39.
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
US20210047423A1
(en)
|
2019-08-16 |
2021-02-18 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
CN115151275A
(zh)
|
2019-08-30 |
2022-10-04 |
耶鲁大学 |
用于向细胞递送核酸的组合物和方法
|
TW202128775A
(zh)
|
2019-10-16 |
2021-08-01 |
英商阿法克塔生命科學有限公司 |
PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分
|
US10945992B1
(en)
|
2019-11-13 |
2021-03-16 |
Tremeau Pharmaceuticals, Inc. |
Dosage forms of rofecoxib and related methods
|
AU2020387709A1
(en)
|
2019-11-18 |
2022-07-07 |
Janssen Biotech, Inc. |
Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
WO2021168373A1
(en)
|
2020-02-21 |
2021-08-26 |
Mitotherapeutix Llc |
Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
|
IL302347A
(en)
|
2020-03-13 |
2023-06-01 |
Janssen Biotech Inc |
Materials and methods for binding siglec-3/cd33
|
US20230181672A1
(en)
|
2020-05-07 |
2023-06-15 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
|
EP4146667A4
(en)
|
2020-05-08 |
2024-06-19 |
Georgiamune Inc. |
Akt3 modulators
|
AU2021276410A1
(en)
|
2020-05-19 |
2023-01-19 |
Orna Therapeutics, Inc. |
Circular RNA compositions and methods
|
WO2021237068A2
(en)
|
2020-05-21 |
2021-11-25 |
Board Of Regents, The University Of Texas System |
T cell receptors with vgll1 specificity and uses thereof
|
WO2021245285A1
(en)
|
2020-06-05 |
2021-12-09 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer based on molecular subtypes
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
AU2021331785A1
(en)
|
2020-08-31 |
2023-03-30 |
Gennao Bio, Inc. |
Compositions and methods for delivery of nucleic acids to cells
|
CA3173951A1
(en)
|
2020-09-04 |
2022-03-10 |
Emily VOIGT |
Genetically-adjuvanted rna vaccines
|
CA3174411A1
(en)
|
2020-09-04 |
2022-03-10 |
Ryan M. Kramer |
Co-lyophilized rna and nanostructured lipid carrier
|
WO2022051023A1
(en)
|
2020-09-04 |
2022-03-10 |
Infectious Disease Research Institute |
Live-attenuated rna hybrid vaccine technology
|
MX2023004395A
(es)
|
2020-10-16 |
2023-05-22 |
Univ Georgia |
Glicoconjugados.
|
EP4059498A1
(en)
|
2021-03-16 |
2022-09-21 |
Centre Hospitalier Universitaire Vaudois (CHUV) |
Methods and compositions for treating conditions associated with hypermineralization
|
WO2022201052A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Antibody targeting cd22 and cd79b
|
US11161833B1
(en)
|
2021-04-09 |
2021-11-02 |
Tremeau Pharmaceuticals, Inc. |
Deuterated etoricoxib, methods of manufacture, and use thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
US20240279687A1
(en)
|
2021-06-07 |
2024-08-22 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
EP4368203A4
(en)
|
2021-07-05 |
2025-09-24 |
Wuhan Neurophth Biotechnology Ltd Company |
CONSTRUCTION AND USE OF ANTI-VEGF ANTIBODIES IN AN IN VIVO EXPRESSION SYSTEM
|
MX2024001597A
(es)
|
2021-08-06 |
2024-02-15 |
Wuhan Neurophth Biotechnology Ltd Company |
Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4.
|
US12129302B2
(en)
|
2021-08-25 |
2024-10-29 |
Ibio, Inc. |
Anti-CD-25 antibody
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
TW202332694A
(zh)
|
2021-10-07 |
2023-08-16 |
英商阿凡克塔生命科學公司 |
血清半衰期延長之pd-l1結合多肽
|
CA3236235A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023088227A1
(zh)
|
2021-11-16 |
2023-05-25 |
上海舶望制药有限公司 |
抑制血管紧张素原(agt)蛋白表达的组合物和方法
|
MX2024006348A
(es)
|
2021-11-29 |
2024-06-11 |
Shanghai Argo Biopharmaceutical Co Ltd |
Composiciones y metodos para inhibir la expresion de la proteina del virus de la hepatitis b (vhb).
|
TW202345865A
(zh)
|
2022-01-24 |
2023-12-01 |
大陸商上海舶望製藥有限公司 |
抑制LPA(Apo(a))蛋白表達的組合物和方法
|
JP2025509078A
(ja)
|
2022-02-10 |
2025-04-11 |
アフィセル セラピューティクス カンパニー リミテッド |
Cd40lに特異的に結合するステフィンaタンパク質変異体及びその用途
|
WO2023212483A1
(en)
|
2022-04-29 |
2023-11-02 |
Purinomia Biotech, Inc. |
Methods and compositions for treating eosinophil driven diseases and disorders
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
US12297285B2
(en)
|
2022-06-24 |
2025-05-13 |
Orna Therapeutics, Inc. |
Circular RNA encoding chimeric antigen receptors targeting BCMA
|
AU2023336224A1
(en)
|
2022-09-09 |
2025-03-27 |
Access To Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
WO2024055034A1
(en)
|
2022-09-09 |
2024-03-14 |
Yale University |
Proteolysis targeting antibodies and methods of use thereof
|
AU2023361162A1
(en)
|
2022-10-11 |
2025-05-29 |
Yale University |
Compositions and methods of using cell-penetrating antibodies
|
WO2024094526A1
(en)
|
2022-11-02 |
2024-05-10 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
6-diazo-5-oxo-l-norleucine prodrugs
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
TW202440920A
(zh)
|
2022-12-02 |
2024-10-16 |
大陸商上海舶望製藥有限公司 |
雙環脫鹼基核酸類似物以及由它們製備的寡聚化合物
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024205657A2
(en)
|
2023-03-29 |
2024-10-03 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024233308A2
(en)
|
2023-05-05 |
2024-11-14 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|
WO2024263649A1
(en)
|
2023-06-19 |
2024-12-26 |
Yale University |
Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
|
WO2025007148A1
(en)
|
2023-06-30 |
2025-01-02 |
Orna Therapeutics, Inc. |
Polymer lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2025021993A1
(en)
|
2023-07-27 |
2025-01-30 |
Omnilinx Therapeutics Ag |
Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
|
WO2025029769A1
(en)
|
2023-07-31 |
2025-02-06 |
Eli Lilly And Company |
Solid forms of a kv1.3 potassium shaker channel blockers and method of using the same
|
US11957676B1
(en)
|
2023-08-07 |
2024-04-16 |
Zetagen Therapeutics, Inc. |
Controlled release formulation and minimally invasive method of administration to locally treat cancer
|
WO2025049690A1
(en)
|
2023-08-29 |
2025-03-06 |
Orna Therapeutics, Inc. |
Circular polyethylene glycol lipids
|
WO2025052303A1
(en)
|
2023-09-08 |
2025-03-13 |
Beigene Switzerland Gmbh |
Circular rna and preparation methods thereof
|
EP4537907A1
(en)
|
2023-10-10 |
2025-04-16 |
Enthera S.r.l. |
Cd248 inhibitors and uses thereof
|
WO2025097000A1
(en)
|
2023-11-01 |
2025-05-08 |
Yale University |
Antibody-based methods for treating polycystic kidney disease
|
WO2025117969A1
(en)
|
2023-12-01 |
2025-06-05 |
Orna Therapeutics, Inc. |
Process for manufacturing lipid nanoparticles
|